Zynex

Zynex P/CF

Delisted

The P/CF (Price-to-Cash-Flow Ratio) of Zynex (ZYXI) as of Nov 22, 2026 is 0.13. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 0.09 — a change of 39.58% (higher).

P/CF

0.13

YoY

39.58%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Zynex is 2024 0.13 . P/CF (Price-to-Cash-Flow Ratio) of Zynex was 2023 0.09 . It decreases by 39.58% higher compared to the previous year.

The Zynex P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2017
0.20 USD
Jan 1, 2018
0.18 USD
Jan 1, 2019
0.26 USD
Jan 1, 2020
2.04 USD
Jan 1, 2021
0.24 USD
Jan 1, 2022
0.12 USD
Jan 1, 2023
0.09 USD
Jan 1, 2024
0.13 USD
The Zynex P/CF history
YEARP/CFYoY
0.13+39.58%
0.09-22.58%
0.12-49.45%
0.24-88.23%
2.04+670.54%
0.26+49.26%
0.18-12.20%
0.20-79.42%
0.98-79.94%
4.90+181.82%
1.74—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zynex Stock analysis

What does Zynex do? Zynex Inc is an American company that manufactures and distributes medical devices and accessories. The company was founded in 1996 and is headquartered in Englewood, Colorado. In recent years, it has become a major player in the pain therapy market. The history of Zynex began with the development of a neurotherapeutic system called NeuroMove, which aimed to restore mobility in patients with paralysis after strokes or other neurological disorders. The company uses proprietary technology to provide safe and effective electrotherapeutic stimulation, which helps trigger muscle contractions and improve mobility. Over the years, the company has specialized in the development and sale of medical devices for pain therapy and rehabilitation. Zynex's products can be used in various areas, including electrostimulation, TENS and EMS therapy, home diagnostics, as well as blood pressure and oxygen measurement. Zynex offers devices specifically for pain therapy. These devices are used by many doctors and physiotherapists to support patients in their healing process. The company's flagship product is the Nexus D-11 EMS and TENS device, which is capable of conducting multiple pain treatments simultaneously. Another important device from Zynex is the InWave system, which applies FDA-approved electromagnetic wave therapy. The therapy is used for both acute and chronic pain and aims to promote the body's natural healing processes to relieve pain. Zynex also manufactures home diagnostic devices such as the blood sugar monitor and pulse oximeter, which can be regularly used by patients at home to monitor their well-being. These products help individuals develop an understanding of how their body responds to different treatments or environmental conditions. An important aspect of Zynex's business model is collaborating with healthcare customers. The company forms partnerships with medical facilities and practitioners to ensure that its products are effectively and safely utilized. These partnerships often include training programs to ensure that users of each device develop a basic understanding of how it works to ensure quality treatment. Zynex has also established a subsidiary called Zynex Medical Europe, which operates in European regions. The company is based in the Netherlands and is responsible for marketing and distributing Zynex's products in Europe. Overall, Zynex has established itself as a key player in the field of pain therapy and rehabilitation. Through its innovative technology and healthcare partnerships, the company is able to provide the best possible patient care. Zynex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zynex stock

P/CF (Price-to-Cash-Flow Ratio) of Zynex is 0.13 in 2024.

P/CF (Price-to-Cash-Flow Ratio) of Zynex changed from 0.09 to 0.13, representing a 39.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Zynex since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Zynex with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Zynex

All Key Metrics — Zynex